• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Advisory Committees

  • Print
  • Share
  • E-mail

Briefing Information for the July 26, 2012 Meeting of the Dermatologic and Ophthalmic Drugs Advisory Committee

 

Persons with disabilities having problems accessing the PDF file(s) below may call (301) 796-3634 for assistance
 
 
Morning Session:
 
FDA
 
Disclaimer
 
Portions of this document have been determined to be exempt from disclosure under the Freedom of Information Act (the FOIA) (5 U.S.C. § 552).
 
FDA Briefing Information, Lucentis (Ranibizumab Injection), for the July 26, 2012 Meeting of the Dermatologic and Ophthalmic Drugs Advisory Committee (PDF – 1.05MB)
 
 
Genentech, Inc.
 
Disclaimer
 
The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.
 
Genentech Briefing Information, Lucentis (Ranibizumab Injection), for the July 26, 2012 Meeting of the Dermatologic and Ophthalmic Drugs Advisory Committee (PDF – 7.02MB)
 
 
Afternoon Session:
 
FDA
 
Disclaimer
 
Portions of this document have been determined to be exempt from disclosure under the Freedom of Information Act (the FOIA) (5 U.S.C. § 552).
 
FDA Briefing Information, Jetrea (Ocriplasmin Intravitreal Injection), for the July 26, 2012 Meeting of the Dermatologic and Ophthalmic Drugs Advisory Committee (PDF – 986KB)
 
 
ThromboGenics, Inc.
 
Disclaimer
 
The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.
 
ThromboGenics Briefing Information, Jetrea (Ocriplasmin Intravitreal Injection), for the July 26, 2012 Meeting of the Dermatologic and Ophthalmic Drugs Advisory Committee (PDF – 6.96MB)